|
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 15.27 CNY | -0.07% |
|
-0.33% | +5.60% |
| Oct. 27 | Tasly Pharmaceutical's Q3 Profit Rises 17%, Revenue Slips 3%; Shares Down 1% | MT |
| Oct. 24 | Tasly pharmaceutical group Q3 net profit up 16.6% Y/Y | RE |
| Capitalization | 22.83B 3.23B 2.75B 2.57B 2.41B 4.46B 292B 4.85B 29.93B 11.63B 138B 12.14B 11.88B 502B | P/E ratio 2025 * |
19.8x | P/E ratio 2026 * | 16.1x |
|---|---|---|---|---|---|
| Enterprise value | 20.58B 2.92B 2.48B 2.32B 2.17B 4.02B 263B 4.37B 26.98B 10.48B 124B 10.94B 10.71B 453B | EV / Sales 2025 * |
2.31x | EV / Sales 2026 * | 2.17x |
| Free-Float |
49.28% | Yield 2025 * |
3.55% | Yield 2026 * | 4.34% |
| 1 day | -0.07% | ||
| 1 week | -0.33% | ||
| Current month | -0.39% | ||
| 1 month | -1.80% | ||
| 3 months | -6.20% | ||
| 6 months | -7.12% | ||
| Current year | +5.60% |
| 1 week | 15.06 |  | 15.43 |
| 1 month | 15.06 | | 15.91 |
| Current year | 13.51 | | 17.69 |
| 1 year | 13.51 | | 17.69 |
| 3 years | 10.49 | | 18 |
| 5 years | 9.2 | | 18 |
| 10 years | 9.2 | | 34.22 |
| Manager | Title | Age | Since |
|---|---|---|---|
Jin Yong Cai
CEO | Chief Executive Officer | 53 | 2024-05-07 |
Jie Wei
DFI | Director of Finance/CFO | 48 | 2018-07-08 |
Ying Zhao
IRC | Investor Relations Contact | - | - |
| Director | Title | Age | Since |
|---|---|---|---|
Xiao Meng Jiang
BRD | Director/Board Member | 61 | 2007-08-16 |
Ai Jian Wang
BRD | Director/Board Member | 71 | 2021-06-01 |
Jin Yong Cai
BRD | Director/Board Member | 53 | 2006-03-24 |
| Change | 5d. change | 1-year change | 3-years change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -0.07% | -0.33% | +4.30% | +29.74% | 3.23B | |
| -1.10% | -2.56% | -21.38% | -33.76% | 6.37B | |
| +1.03% | +2.54% | -16.62% | +26.96% | 4.4B | |
| +0.50% | -0.43% | +43.39% | +54.05% | 4.35B | |
| -0.96% | -3.80% | +2.70% | -65.62% | 4.18B | |
| -0.50% | +1.35% | -7.12% | -9.40% | 3.64B | |
| -0.12% | -3.08% | -4.04% | -37.18% | 2.45B | |
| +1.99% | -0.93% | +9.03% | -1.32% | 1.95B | |
| -0.70% | +7.64% | +9.50% | +62.99% | 1.81B | |
| -1.60% | -2.17% | -0.51% | +56.00% | 1.75B | |
| Average | -0.15% | +0.12% | +1.93% | +8.25% | 3.41B | |
| Weighted average by Cap. | -0.20% | -0.17% | +0.08% | +1.31% |
| 2025 * | 2026 * | |
|---|---|---|
| Net sales | 8.92B 1.26B 1.07B 1B 941M 1.74B 114B 1.9B 11.69B 4.54B 53.82B 4.74B 4.64B 196B | 9.43B 1.34B 1.14B 1.06B 996M 1.84B 121B 2B 12.37B 4.81B 56.95B 5.02B 4.91B 207B |
| Net income | 1.15B 163M 139M 130M 122M 225M 14.72B 245M 1.51B 587M 6.95B 612M 599M 25.34B | 1.41B 200M 170M 159M 149M 276M 18.07B 301M 1.85B 720M 8.54B 752M 736M 31.11B |
| Net Debt | -2.25B -319M -271M -253M -237M -439M -28.74B -478M -2.95B -1.15B -13.58B -1.2B -1.17B -49.47B | -2.37B -335M -285M -266M -250M -462M -30.26B -503M -3.1B -1.21B -14.29B -1.26B -1.23B -52.08B |
| Date | Price | Change | Volume |
|---|---|---|---|
| 25-12-11 | 15.27 ¥ | -0.07% | 11,115,420 |
| 25-12-11 | 15.28 ¥ | +0.33% | 8,938,360 |
| 25-12-10 | 15.23 ¥ | +0.26% | 7,768,880 |
| 25-12-09 | 15.19 ¥ | -0.52% | 5,461,137 |
| 25-12-08 | 15.27 ¥ | -0.52% | 5,831,300 |
End-of-day quote Shanghai S.E., December 11, 2025
More quotes
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Global Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Global Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite), and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be performed. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of the rankings based on the following ratings: Capital Efficiency (Composite), Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully review the associated descriptions.
Quarterly revenue - Rate of surprise
- Stock Market
- Equities
- 600535 Stock
Select your edition
All financial news and data tailored to specific country editions
